Lung cancer is the most common forms of cancer and the leading cause of deaths. A recent study has been published in the European Journal of Pharmaceutical Sciences. According to this study,…
Tag: Lung Cancer News
Tarlatamab for Small Cell Lung Cancer
Lung cancer is the second most form of cancers and remains the leading cause of cancer deaths. A variety of new treatments are helping to bring down the number of deaths from…
UK Study Shows Ethic And Social Inequalities In Diagnosis Of Lung Cancer
The most comprehensive UK study ever conducted of lung cancer diagnosis has revealed significant disparities among ethnic groups. It has found evidences that people living in most deprived areas were diagnosed with…
Study: Methylmalonic Acid to Weaken Immune Cells in Lung Cancer
According to a new study, a surprising link has been found between methylmalonic Acid and weakening if CD8+ T cells. Moffitt Cancer Center researchers have found how metabolic changes associated with aging…
Study: Physical Tests Vital in Treating Metastatic Lung Cancer
According to a new study from the researchers in Brazil and the United States, simple physical tests like sitting down, standing up and walking can significantly aid physicians in managing treatments for…
FDA Approves Optune Luna for Metastatic NSCLC
U.S. based FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for treatment of patients with metastatic non-small cell lung cancer and whose disease has progressed on or after platinum-based…
Research Finds Useful Information about Natural Killer Cells
The researchers of Trinity College Dublin based at St James’s Hospital have provided useful insights about the behaviour and metabolic function of *natural killer* immune cell resident in the lungs. Their findings…
Hetronifly Recommended for Lung Cancer in European Markets
The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion and recommended for grant of marketing authorization for the medicinal product, Hetronifly in European markets. It is intended…